NEW YORK (GenomeWeb) – Fitch Ratings has affirmed Thermo Fisher Scientific's ratings and its stable rating outlook.

The ratings apply to $12.5 billion of debt as of Dec. 31, 2015 and include BBB ratings for Thermo Fishers' long-term issuer default rating, senior notes, and a bank revolving credit facility; and F2 ratings for its short-term IDR and commercial paper. Fitch also affirmed a BBB rating for Thermo Fisher Subsidiary Life Technologies' long-term IDR and senior notes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.